Trevi Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer SCIASCIA THOMAS unloaded Company’s shares for reported $17365.0 on Mar 25 ’25. In the deal valued at $6.60 per share,2,631 shares were sold. As a result of this transaction, SCIASCIA THOMAS now holds 221,373 shares worth roughly $1.43 million.
Then, GOOD JENNIFER L sold 5,263 shares, generating $34,625 in total proceeds. Upon selling the shares at $6.58, the President & CEO now owns 213,313 shares.
Before that, GOOD JENNIFER L bought 5,263 shares. Trevi Therapeutics Inc shares valued at $34,625 were divested by the Officer at a price of $6.58 per share.
Raymond James upgraded its Trevi Therapeutics Inc [TRVI] rating to a Strong buy from a an Outperform in a research note published on March 10, 2025; the price target was increased to $29 from $9. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early March has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright also remained covering TRVI and reiterated its “Buy” recommendation on December 12, 2024.
Price Performance Review of TRVI
On Friday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock jump 1.89% to $6.47. Over the last five days, the stock has gained 6.59%. Trevi Therapeutics Inc shares have risen nearly 57.04% since the year began. Nevertheless, the stocks have risen 127.02% over the past one year. While a 52-week high of $7.39 was reached on 03/10/25, a 52-week low of $2.30 was recorded on 01/22/25. SMA at 50 days reached $5.62, while 200 days put it at $3.86.
Levels Of Support And Resistance For TRVI Stock
The 24-hour chart illustrates a support level at 6.24, which if violated will result in even more drops to 6.00. On the upside, there is a resistance level at 6.60. A further resistance level may holdings at 6.72. The Relative Strength Index (RSI) on the 14-day chart is 61.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 1.22%. Stochastics %K at 93.76% indicates the stock is a selling.
How much short interest is there in Trevi Therapeutics Inc?
A steep rise in short interest was recorded in Trevi Therapeutics Inc stocks on 2025-04-15, growing by 1.23 million shares to a total of 5.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 4.68 million shares. There was a rise of 20.88%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 30, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.
